PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34145369-0	2021	Combination of 131I-trastuzumab and lanatoside C enhanced therapeutic efficacy in HER2 positive tumor model.	lanatoside C	36-48	erb-b2 receptor tyrosine kinase 2	Mus musculus	82-86	
34145369-4	2021	Biodistribution studies using 131I-trastuzumab or combination of 131I-trastuzumab and lanatoside C showed tumor uptake in BALB/c nude mice bearing HER2 positive NCI-N87 tumor xenograft model.	lanatoside C	86-98	erb-b2 receptor tyrosine kinase 2	Mus musculus	147-151	
34145369-8	2021	Taken together, our data suggest that combination of 131I-trastuzumab and lanatoside C might be a potential synergistic treatment for radioimmunotherapy to control the HER2 positive tumor.	lanatoside C	74-86	erb-b2 receptor tyrosine kinase 2	Mus musculus	168-172